|
2020-03-17 |
2020-03-16 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
200
-0.5%
85.59
17,118
USD
|
200
-0.5%
|
85.59
|
17,118
USD
|
|
|
2020-03-12 |
2020-03-11 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
2,175
-5.1%
104.25
226,744
USD
|
2,175
-5.1%
|
104.25
|
226,744
USD
|
|
|
2020-03-12 |
2020-03-11 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
Officer
|
2,501
-3.5%
104.25
260,729
USD
|
2,501
-3.5%
|
104.25
|
260,729
USD
|
|
|
2020-03-12 |
2020-03-10 |
PS
Planned sale
|
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
Executive Director
|
100
-0.0%
112.19
11,219
USD
|
100
-0.0%
|
112.19
|
11,219
USD
|
|
|
2020-03-10 |
2020-03-06 |
PS
Planned sale
|
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
Executive Director
|
2,000
-0.9%
116.27
232,544
USD
|
2,000
-0.9%
|
116.27
|
232,544
USD
|
|
|
2020-03-10 |
2020-03-06 |
PS
Planned sale
|
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
Executive Director
|
3,937
-1.7%
115.45
454,535
USD
|
3,937
-1.7%
|
115.45
|
454,535
USD
|
|
|
2020-03-10 |
2020-03-06 |
PS
Planned sale
|
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
Executive Director
|
16,426
-6.6%
114.24
1,876,441
USD
|
16,426
-6.6%
|
114.24
|
1,876,441
USD
|
|
|
2020-03-10 |
2020-03-06 |
PS
Planned sale
|
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
Executive Director
|
36,790
-12.9%
113.65
4,181,257
USD
|
36,790
-12.9%
|
113.65
|
4,181,257
USD
|
|
|
2020-03-10 |
2020-03-06 |
PS
Planned sale
|
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
Executive Director
|
171,025
-37.4%
112.21
19,190,202
USD
|
171,025
-37.4%
|
112.21
|
19,190,202
USD
|
|
|
2020-02-28 |
2020-02-27 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
690
-1.7%
109.02
75,224
USD
|
690
-1.7%
|
109.02
|
75,224
USD
|
|
|
2020-02-28 |
2020-02-27 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
1,100
-2.8%
109.02
119,922
USD
|
1,100
-2.8%
|
109.02
|
119,922
USD
|
|
|
2020-02-28 |
2020-02-27 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
Officer
|
789
-1.1%
109.02
86,017
USD
|
789
-1.1%
|
109.02
|
86,017
USD
|
|
|
2020-02-28 |
2020-02-26 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
321
-0.8%
111.09
35,660
USD
|
321
-0.8%
|
111.09
|
35,660
USD
|
|
|
2020-02-28 |
2020-02-26 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
510
-1.2%
111.09
56,656
USD
|
510
-1.2%
|
111.09
|
56,656
USD
|
|
|
2020-02-28 |
2020-02-26 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
Officer
|
368
-0.5%
111.09
40,881
USD
|
368
-0.5%
|
111.09
|
40,881
USD
|
|
|
2020-02-26 |
2020-02-25 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
Officer
|
405
-0.6%
112.73
45,656
USD
|
405
-0.6%
|
112.73
|
45,656
USD
|
|
|
2020-02-26 |
2020-02-25 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
598
-1.4%
112.73
67,413
USD
|
598
-1.4%
|
112.73
|
67,413
USD
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
8,853
-19.5%
106.51
942,942
USD
|
8,853
-19.5%
|
106.51
|
942,942
USD
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
69,003
-60.3%
105.45
7,276,504
USD
|
69,003
-60.3%
|
105.45
|
7,276,504
USD
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
7,423
-6.1%
106.51
790,646
USD
|
7,423
-6.1%
|
106.51
|
790,646
USD
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
58,258
-32.4%
105.46
6,143,772
USD
|
58,258
-32.4%
|
105.46
|
6,143,772
USD
|
|
|
2019-12-04 |
2019-11-27 |
S
Sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
500
-1.3%
107.83
53,915
USD
|
500
-1.3%
|
107.83
|
53,915
USD
|
|
|
2019-12-04 |
2019-11-27 |
S
Sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
32,193
-44.6%
107.53
3,461,552
USD
|
32,193
-44.6%
|
107.53
|
3,461,552
USD
|
|
|
2019-12-04 |
2019-11-27 |
S
Sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
11,863
-14.1%
107.15
1,271,097
USD
|
11,863
-14.1%
|
107.15
|
1,271,097
USD
|
|
|
2019-11-27 |
2019-11-26 |
S
Sale
|
WILENSKY GAIL R
|
8,000
-34.9%
107.17
857,352
USD
|
8,000
-34.9%
|
107.17
|
857,352
USD
|
|
|
2019-09-19 |
2019-09-17 |
PS
Planned sale
|
DEPPE MICHAEL J
VP, Corp. Controller & CAO
|
5,000
-17.4%
106.00
530,000
USD
|
5,000
-17.4%
|
106.00
|
530,000
USD
|
|
|
2019-06-17 |
2019-06-13 |
S
Sale
|
GUINAN MARK
Executive Vice President & CFO
|
73,005
-52.5%
100.00
7,300,500
USD
|
73,005
-52.5%
|
100.00
|
7,300,500
USD
|
|
|
2019-06-17 |
2019-06-13 |
S
Sale
|
RUSCKOWSKI STEPHEN H
Chairman, President and CEO
Executive Director
|
244,565
-53.4%
100.00
24,456,500
USD
|
244,565
-53.4%
|
100.00
|
24,456,500
USD
|
|
|
2019-04-26 |
2019-04-24 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
|
47,574
-56.6%
95.00
4,519,530
USD
|
47,574
-56.6%
|
95.00
|
4,519,530
USD
|
|
|
2019-04-10 |
2019-04-08 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
|
2,100
-5.4%
90.70
190,476
USD
|
2,100
-5.4%
|
90.70
|
190,476
USD
|
|
|
2019-04-10 |
2019-04-08 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
|
5,900
-13.2%
90.15
531,856
USD
|
5,900
-13.2%
|
90.15
|
531,856
USD
|
|
|
2019-04-08 |
2019-04-04 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
|
5,890
-8.0%
90.59
533,587
USD
|
5,890
-8.0%
|
90.59
|
533,587
USD
|
|
|
2019-04-08 |
2019-04-04 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
|
60,492
-45.2%
90.59
5,480,152
USD
|
60,492
-45.2%
|
90.59
|
5,480,152
USD
|
|
|
2019-03-05 |
2019-03-04 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
3,892
-9.2%
86.81
337,865
USD
|
3,892
-9.2%
|
86.81
|
337,865
USD
|
|
|
2019-03-05 |
2019-03-04 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
3,373
-7.9%
86.81
292,810
USD
|
3,373
-7.9%
|
86.81
|
292,810
USD
|
|
|
2019-02-28 |
2019-02-27 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
1,144
-2.9%
86.51
98,967
USD
|
1,144
-2.9%
|
86.51
|
98,967
USD
|
|
|
2019-02-28 |
2019-02-27 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
1,048
-2.6%
86.51
90,662
USD
|
1,048
-2.6%
|
86.51
|
90,662
USD
|
|
|
2019-02-28 |
2019-02-26 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
352
-0.9%
87.06
30,645
USD
|
352
-0.9%
|
87.06
|
30,645
USD
|
|
|
2019-02-28 |
2019-02-26 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
364
-0.9%
87.06
31,690
USD
|
364
-0.9%
|
87.06
|
31,690
USD
|
|
|
2019-02-27 |
2019-02-25 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
326
-0.8%
88.23
28,763
USD
|
326
-0.8%
|
88.23
|
28,763
USD
|
|
|
2019-02-27 |
2019-02-25 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
336
-0.8%
88.23
29,645
USD
|
336
-0.8%
|
88.23
|
29,645
USD
|
|
|
2019-02-25 |
2019-02-22 |
S
Sale
|
WILENSKY GAIL R
Non-Executive Director
|
8,000
-23.1%
87.78
702,216
USD
|
8,000
-23.1%
|
87.78
|
702,216
USD
|
|
|
2018-07-12 |
2018-07-10 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
40,328
-51.3%
112.00
4,516,736
USD
|
40,328
-51.3%
|
112.00
|
4,516,736
USD
|
|
|
2018-07-12 |
2018-07-10 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
Officer
|
30,780
-43.6%
113.07
3,480,141
USD
|
30,780
-43.6%
|
113.07
|
3,480,141
USD
|
|
|
2018-07-05 |
2018-07-02 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
781
-2.0%
110.12
86,007
USD
|
781
-2.0%
|
110.12
|
86,007
USD
|
|
|
2018-07-05 |
2018-07-02 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
7,066
-15.4%
109.63
774,624
USD
|
7,066
-15.4%
|
109.63
|
774,624
USD
|
|
|
2018-07-05 |
2018-07-02 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
5,583
-10.8%
110.07
614,498
USD
|
5,583
-10.8%
|
110.07
|
614,498
USD
|
|
|
2018-07-05 |
2018-07-02 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
33,345
-39.3%
109.60
3,654,479
USD
|
33,345
-39.3%
|
109.60
|
3,654,479
USD
|
|
|
2018-07-05 |
2018-07-02 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
1,496
-3.2%
110.12
164,743
USD
|
1,496
-3.2%
|
110.12
|
164,743
USD
|
|
|
2018-07-05 |
2018-07-02 |
PS
Planned sale
|
Cunningham Everett
SVP, Commercial
Officer
|
19,798
-29.5%
109.64
2,170,692
USD
|
19,798
-29.5%
|
109.64
|
2,170,692
USD
|
|
|
2018-05-30 |
2018-05-29 |
S
Sale
|
LEIDEN JEFFREY M
Non-Executive Director
|
1,644
-21.5%
105.61
173,623
USD
|
1,644
-21.5%
|
105.61
|
173,623
USD
|
|
|
2018-05-29 |
2018-05-25 |
PS
Planned sale
|
RUSCKOWSKI STEPHEN H
Chairman, President and CEO
Executive Director
|
168,490
-46.9%
107.00
18,028,430
USD
|
168,490
-46.9%
|
107.00
|
18,028,430
USD
|
|
|
2018-05-29 |
2018-05-25 |
PS
Planned sale
|
GUINAN MARK
Executive Vice President & CFO
Officer
|
24,960
-30.0%
106.14
2,649,229
USD
|
24,960
-30.0%
|
106.14
|
2,649,229
USD
|
|
|
2018-05-29 |
2018-05-25 |
PS
Planned sale
|
GUINAN MARK
Executive Vice President & CFO
Officer
|
36,573
-30.5%
105.42
3,855,453
USD
|
36,573
-30.5%
|
105.42
|
3,855,453
USD
|
|
|
2018-03-12 |
2018-03-08 |
PS
Planned sale
|
Cohen Jon R
SVP & Group Exec. Diag. Sol.
|
7,773
-19.7%
104.77
814,377
USD
|
7,773
-19.7%
|
104.77
|
814,377
USD
|
|
|
2018-03-12 |
2018-03-08 |
PS
Planned sale
|
Cohen Jon R
SVP & Group Exec. Diag. Sol.
|
2,800
-6.6%
104.77
293,356
USD
|
2,800
-6.6%
|
104.77
|
293,356
USD
|
|
|
2018-03-12 |
2018-03-08 |
PS
Planned sale
|
Cohen Jon R
SVP & Group Exec. Diag. Sol.
|
34,168
-44.7%
104.09
3,556,479
USD
|
34,168
-44.7%
|
104.09
|
3,556,479
USD
|
|
|
2018-03-12 |
2018-03-08 |
PS
Planned sale
|
Cohen Jon R
SVP & Group Exec. Diag. Sol.
|
1,300
-1.7%
104.77
136,197
USD
|
1,300
-1.7%
|
104.77
|
136,197
USD
|
|
|
2018-03-12 |
2018-03-08 |
PS
Planned sale
|
Cohen Jon R
SVP & Group Exec. Diag. Sol.
|
18,164
-18.9%
104.09
1,890,654
USD
|
18,164
-18.9%
|
104.09
|
1,890,654
USD
|
|
|
2018-03-12 |
2018-03-08 |
PS
Planned sale
|
Cohen Jon R
SVP & Group Exec. Diag. Sol.
|
1,427
-1.5%
104.76
149,493
USD
|
1,427
-1.5%
|
104.76
|
149,493
USD
|
|
|
2018-03-12 |
2018-03-08 |
PS
Planned sale
|
Cohen Jon R
SVP & Group Exec. Diag. Sol.
|
18,037
-15.6%
104.09
1,877,381
USD
|
18,037
-15.6%
|
104.09
|
1,877,381
USD
|
|
|
2018-03-06 |
2018-03-05 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
|
5,556
-7.6%
101.00
561,156
USD
|
5,556
-7.6%
|
101.00
|
561,156
USD
|
|
|
2018-03-06 |
2018-03-05 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
|
5,122
-12.1%
101.00
517,322
USD
|
5,122
-12.1%
|
101.00
|
517,322
USD
|
|
|
2018-03-06 |
2018-03-05 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
|
4,128
-9.4%
101.00
416,928
USD
|
4,128
-9.4%
|
101.00
|
416,928
USD
|
|
|
2018-03-01 |
2018-02-28 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
|
572
-0.8%
104.99
60,054
USD
|
572
-0.8%
|
104.99
|
60,054
USD
|
|
|
2018-03-01 |
2018-02-28 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
|
648
-1.7%
104.99
68,034
USD
|
648
-1.7%
|
104.99
|
68,034
USD
|
|
|
2018-03-01 |
2018-02-28 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
|
496
-1.2%
104.99
52,075
USD
|
496
-1.2%
|
104.99
|
52,075
USD
|
|
|
2018-03-01 |
2018-02-27 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
|
1,248
-1.8%
104.10
129,917
USD
|
1,248
-1.8%
|
104.10
|
129,917
USD
|
|
|
2018-03-01 |
2018-02-27 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
|
1,150
-3.0%
104.10
119,715
USD
|
1,150
-3.0%
|
104.10
|
119,715
USD
|
|
|
2018-03-01 |
2018-02-27 |
PS
Planned sale
|
PREVOZNIK MICHAEL E
SVP & General Counsel
|
927
-2.3%
104.10
96,501
USD
|
927
-2.3%
|
104.10
|
96,501
USD
|
|
|
2018-02-27 |
2018-02-26 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
Officer
|
397
-0.6%
102.74
40,788
USD
|
397
-0.6%
|
102.74
|
40,788
USD
|
|
|
2018-02-27 |
2018-02-26 |
PS
Planned sale
|
Davis J. E.
EVP, General Diagnostics
Officer
|
494
-1.2%
102.74
50,754
USD
|
494
-1.2%
|
102.74
|
50,754
USD
|
|
|
2018-02-27 |
2018-02-26 |
S
Sale
|
Klug Robert A
VP, Corporate Controller
Officer
|
1,157
-22.9%
103.66
119,932
USD
|
1,157
-22.9%
|
103.66
|
119,932
USD
|
|
|
2018-01-31 |
2018-01-29 |
PS
Planned sale
|
RUSCKOWSKI STEPHEN H
Chairman, President and CEO
Executive Director
|
106,840
-39.1%
107.00
11,431,880
USD
|
106,840
-39.1%
|
107.00
|
11,431,880
USD
|
|
|
2018-01-26 |
2018-01-24 |
PS
Planned sale
|
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
Officer
|
21,294
-23.5%
104.00
2,214,576
USD
|
21,294
-23.5%
|
104.00
|
2,214,576
USD
|
|
